MedTrace Logo

A Study of HDM1002 Tablets on Cardiac Repolarization in Healthy Subjects

NCT07594847 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2026-05-19

No results posted yet for this study

Summary

The aim of this trial is to evaluate the effect of a single oral dose of HDM1002 tablets on the QT/QTc interval in healthy subjects.

Conditions

  • Healthy Adult Subject

Interventions

DRUG

HDM1002 200 mg

HDM1002 tablet, oral, 200 mg single dose

DRUG

HDM1002 400 mg

HDM1002 tablet, oral, 400 mg single dose

DRUG

Placebo

Placebo tablet, oral, single dose

DRUG

Moxifloxacin 400 mg

Moxifloxacin tablet, oral, 400 mg single dose

Sponsors & Collaborators

  • Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-07
Primary Completion
2026-09-25
Completion
2026-11-06
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07594847 on ClinicalTrials.gov